Interim Report for Ortivus AB (publ) for the period January-March 2026
2026-05-07 08:30
“We are fully embracing AI, both in our products and in our internal operations.”
January-March 2026
- Net sales increased with 18% and amounted to SEK 21.5 (18.1) million.
- The gross margin increased to 47 (42)%.
- EBITDA amounted to SEK 1.7 (-1.1) million.
- Adjusted EBITDA* amounted to SEK 1.7 (-1.1) million.
- Net profit after tax amounted to SEK -1.3 (-2.4) million.
- Earnings per share before and after dilution amounted to SEK -0.02 (-0.06).
Significant events during and after the end of the period
- In January, Ortivus announced that Ponderus Invest AB held 80% of the shares and 70.1% of the total voting rights in the company following the mandatory cash offer.
- In February, Minni Raij assumed the position of Chief Financial Officer.
- In March, Ortivus strengthened its liquidity through an extended loan from Ponderus Invest to accelerate the company’s growth strategy. As a result, the credit facility was increased from SEK 20 million to SEK 25 million.
- In April, Matti Zemack was appointed new Chief Product Officer. Zemack will be responsible for the company’s product vision and product development, as well as driving the next generation of Ortivus’ innovative medical technology solutions within e-health.
- In April, Ortivus held its annual user forum in Southampton, UK. With strong attendance from UK customers, new solutions within the MobiMed platform were discussed and presented.
- Ortivus has scheduled its Annual General Meeting for 27 May 2026.
- In May, Ortivus announced that the company had divested all its shares in the technology company H&E Solutions AB for a purchase price of SEK 5.2 million. The sale generated an accounting profit of SEK 2.9 million and strengthened Ortivus’ liquidity, while the successful collaboration on MobiMed enRoute continues unchanged.